Perimeter Medical Imaging AI, Inc. (PINK) Earnings Call Transcripts

Perimeter Medical Imaging AI, Inc.'s Latest Earnings Call - Q1 FY2026

In Q1 2026, Perimeter Medical Imaging AI, Inc. reported revenue of $385,000, all from recurring sources, reflecting a 14% year-over-year growth. The company achieved a net loss of $3 million, improving 31% from the previous year. Management highlighted the FDA PMA approval of the Claire device in March 2026 as a pivotal moment, signaling potential for rapid growth as they transition from the S-Series to the next-generation product. The company maintained a cautious yet optimistic outlook for the remainder of the year, with plans to expand their sales team and capitalize on a strong pipeline of qualified leads.

Reported metrics

Guidance from management

Management expressed confidence in starting to see commercial traction with the Claire device in the second half of 2026, while also focusing on expanding their sales team and pursuing reimbursement opportunities.

What management said

Yes. So we're testing, and we've been able to sign, obviously, been quoting and getting business done at a price that is -- it is not going to be at the same rate. So it's going to be relatively higher, significantly higher, let's say, than the F-Series pricing. So we're not talking about specific pricing at this point as we are testing out the market. But I think you'll be able to see as the financials start to come...

Yes, it was down slightly from Q4 to Q1. There is some seasonality built into that, of course, with the way economics and people's health plan stuff coverage work. Q4 ends up being a very large quarter, both because of breast cancer awareness month and then people trying to get through the deductibles. So it was down quarter-on-quarter. But Q2 is looking to be right on track again. So we're seeing that bounce back no...

What analysts pressed on

Analysts raised questions about the timeline for installations and the conversion process from existing S-Series users to the Claire device. There are concerns regarding the pace of customer adoption and the potential impact on revenue growth in the near term.

Main topics on the call

• FDA PMA Approval of Claire Device — The FDA PMA approval for the Claire device in March 2026 is seen as a major milestone, allowing the company to engage with potential customers. CEO Adrian Mendes stated, "This achievement represents a major validation of...
• Recurring Revenue Growth — Perimeter reported recurring revenue of $385,000 in Q1 2026, a 14% increase year-over-year. This growth is attributed to the sale of F-Series consumables and system leases, indicating strong demand from existing customer...
• Cost Management — Operating expenses decreased by 30% to $3.2 million, contributing to a net loss reduction of 31%. CFO Sara Brien noted, "We continue to carefully manage our resources as we grow," highlighting effective cost control meas...
• Sales Pipeline Development — The company has built a sales funnel of close to 50 qualified leads for the Claire device, with over a dozen in active management stages. Abbey Goodman emphasized that they expect to see commercial traction in the second...

Read the full Perimeter Medical Imaging AI, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 20 Perimeter Medical Imaging AI, Inc. earnings call transcripts on record, spanning October 27, 2022 to May 28, 2026. Based on this history, Perimeter Medical Imaging AI, Inc. reports quarterly. The most recent call on file is dated May 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PINK

Exchange

TSXV

Country

CA

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

20

First call

October 27, 2022

Most recent

May 28, 2026

Reporting cadence

quarterly